Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

The purpose of this study is to assess the safety, feasibility, and performance of the C2
Focal Cryoablation Device in patients with Barrett's Esophagus (BE). At 6 to 8 weeks, the
patient will receive a follow-endoscopy to assess stricture formation along with biopsy
samples taken.

Post-operative pain will be noted. Additionally, biopsy samples will be evaluated for the
presence of residual Barrett's Esophagus. Through evaluation of the histological results,
treatment parameters for the ablation of human esophageal epithelium will be better
understood.

Evaluations include, but are not limited to the following:

- Deployment ease/scope compatibility.

- Device malfunctions.

- Time of catheter deployment.

- Adverse events.

- Stricture formation at 6 to 8 weeks.

- Patient Pain.

- Histological evaluation of treatment zone at 6 to 8 weeks for presence of residual
Barrett's Esophagus.

Inclusion Criteria:

1. Patients scheduled for ablation, EMR, and/or surveillance for BE (with or without
dysplasia). Patient is 18 to 80 years of age at the time of consent (inclusive).

2. Patient has provided written Informed Consent (IC) using an Informed Consent Form
(ICF) that has been approved by the Institution's reviewing IRB/EC.

3. Patient is willing and able to comply with all Clinical Investigation Plan (CIP)
requirements.

4. Patient is deemed operable per standard institutional criteria.

Exclusion Criteria:

1. Patient with endoscopically active inflammation in the treatment zone

2. Esophageal stenosis preventing advancement of a therapeutic endoscope and/or within 4
cm of treatment zone.

3. Patient has a known history of unresolved drug or alcohol dependency that would limit
ability to comprehend or follow instructions related to informed consent, post
treatment instructions or follow-up guidelines.

4. Patient refuses or is unable to provide written informed consent.

5. Patients that are pregnant.